Richard Young - CAMP4 THERAPEUTICS Founder Director
| CAMP Stock | USD 5.78 0.45 8.44% |
Director
Richard Young is Founder Director of CAMP4 THERAPEUTICS PORATION
| Age | 70 |
| Phone | (617) 651-8867 |
| Web | https://www.camp4tx.com |
Richard Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Young against CAMP4 THERAPEUTICS stock is an integral part of due diligence when investing in CAMP4 THERAPEUTICS. Richard Young insider activity provides valuable insight into whether CAMP4 THERAPEUTICS is net buyers or sellers over its current business cycle. Note, CAMP4 THERAPEUTICS insiders must abide by specific rules, including filing SEC forms every time they buy or sell CAMP4 THERAPEUTICS'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Young over three months ago Disposition of 34837 shares by Richard Young of Syros Pharmaceuticals at 5.12 subject to Rule 16b-3 | ||
Richard Young over a year ago Exercise or conversion by Richard Young of 2666 shares of Syros Pharmaceuticals subject to Rule 16b-3 |
Similar Executives
| Found 8 records | DIRECTOR Age | ||
| CFA CMA | Telesat Corp | N/A | |
| Keith Barnes | Knowles Cor | 69 | |
| Ronald Jankov | Knowles Cor | 61 | |
| Christopher Genualdi | NETGEAR | N/A | |
| Cheryl Shavers | Knowles Cor | 67 | |
| Didier Hirsch | Knowles Cor | 69 | |
| Hermann Eul | Knowles Cor | 62 | |
| Ye Li | Knowles Cor | 53 | |
CAMP4 THERAPEUTICS Leadership Team
Elected by the shareholders, the CAMP4 THERAPEUTICS's board of directors comprises two types of representatives: CAMP4 THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CAMP4. The board's role is to monitor CAMP4 THERAPEUTICS's management team and ensure that shareholders' interests are well served. CAMP4 THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CAMP4 THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Gold, Chief Officer | ||
| John Partain, Interim Experience | ||
| Erik Schulz, Interim Officer | ||
| Joshua MandelBrehm, President CEO | ||
| Christian Horne, Interim Sales | ||
| Brett Jackson, Senior Logistics | ||
| Mark Gaydos, Chief Officer | ||
| Michael Zachan, Senior Unit | ||
| Nathan Lowstuter, Senior Officer | ||
| Xiaolian Zhang, Senior Analysis | ||
| Caleb Moore, Chief Operations | ||
| Maurizio Iperti, President Automotive | ||
| Richard Young, Founder Director | ||
| David Bumcrot, Chief Research | ||
| Daniel Tardiff, VP Discovery | ||
| Monica Berkel, Senior President | ||
| Michelle Gates, Senior Officer | ||
| Chris Adams, President CEO | ||
| Leonard MD, Founder | ||
| Jeffery Gardner, Independent Director | ||
| Richard Scott, Chief VP | ||
| Scott Tripp, VP Operations | ||
| MD MBA, Chief Officer | ||
| Richard Vitelle, CFO, Executive VP, Corporate Secretary and Treasurer | ||
| Anand Rau, VP CTO | ||
| Jikun Kim, Senior CFO | ||
| Satya Kuchimanchi, Senior Operations |
CAMP4 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CAMP4 THERAPEUTICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 318.57 X | ||||
| Revenue | 186.23 M | ||||
| EBITDA | (8.72 M) | ||||
| Net Income | (49.29 M) | ||||
| Cash And Equivalents | 47.72 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 178.68 M | ||||
| Current Ratio | 1.86 X | ||||
| Book Value Per Share | (45.01) X | ||||
| Cash Flow From Operations | (44.16 M) |
Pair Trading with CAMP4 THERAPEUTICS
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CAMP4 THERAPEUTICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CAMP4 THERAPEUTICS will appreciate offsetting losses from the drop in the long position's value.Moving against CAMP4 Stock
| 0.73 | VINC | Vincerx Pharma | PairCorr |
| 0.46 | DTIL | Precision BioSciences | PairCorr |
| 0.44 | DRTS | Alpha Tau Medical | PairCorr |
| 0.38 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to CAMP4 THERAPEUTICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CAMP4 THERAPEUTICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CAMP4 THERAPEUTICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CAMP4 THERAPEUTICS PORATION to buy it.
The correlation of CAMP4 THERAPEUTICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CAMP4 THERAPEUTICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CAMP4 THERAPEUTICS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CAMP4 THERAPEUTICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.